| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10953018 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US10624850 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US9974794 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9808465 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9561229 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US11744800 | HERON THERAPS INC | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(11 years from now) | |
| US11878074 | HERON THERAPS INC | Methods of use of emulsion formulations of an NK-1 receptor antagonist |
Sep, 2035
(11 years from now) | |
| US10500208 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974793 | HERON THERAPS INC | Emulsion formulations of aprepitant |
Sep, 2035
(11 years from now) | |
| US9974742 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
| US11173118 | HERON THERAPS INC | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
Sep, 2035
(11 years from now) | |
Aponvie is owned by Heron Theraps Inc.
Aponvie contains Aprepitant.
Aponvie has a total of 11 drug patents out of which 0 drug patents have expired.
Aponvie was authorised for market use on 16 September, 2022.
Aponvie is available in emulsion;intravenous dosage forms.
Aponvie can be used as a method for preventing post-operative nausea and vomiting, a method of administering aprepitant for prevention of post-operative nausea and vomiting, a method for preventing of post-operative nausea and vomiting.
The generics of Aponvie are possible to be released after 18 September, 2035.
Drugs and Companies using APREPITANT ingredient
Market Authorisation Date: 16 September, 2022
Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting; A method for preventing of post-operative nausea and vomiting; A method for preventing post-operative nausea ...
Dosage: EMULSION;INTRAVENOUS
APONVIE family patents
